BNR vs. SERA, LFMD, BDSX, QIPT, CORBF, EUDA, PIII, XGN, ENZ, and TOI
Should you be buying Burning Rock Biotech stock or one of its competitors? The main competitors of Burning Rock Biotech include Sera Prognostics (SERA), LifeMD (LFMD), Biodesix (BDSX), Quipt Home Medical (QIPT), Global Cord Blood (CORBF), EUDA Health (EUDA), P3 Health Partners (PIII), Exagen (XGN), Enzo Biochem (ENZ), and Oncology Institute (TOI). These companies are all part of the "healthcare" industry.
Burning Rock Biotech vs.
Burning Rock Biotech (NASDAQ:BNR) and Sera Prognostics (NASDAQ:SERA) are both small-cap business services companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends.
30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 15.8% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Sera Prognostics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -83.50%. Sera Prognostics' return on equity of -51.73% beat Burning Rock Biotech's return on equity.
In the previous week, Sera Prognostics had 17 more articles in the media than Burning Rock Biotech. MarketBeat recorded 18 mentions for Sera Prognostics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.40 beat Sera Prognostics' score of 0.40 indicating that Burning Rock Biotech is being referred to more favorably in the media.
Sera Prognostics received 5 more outperform votes than Burning Rock Biotech when rated by MarketBeat users. Likewise, 38.46% of users gave Sera Prognostics an outperform vote while only 31.25% of users gave Burning Rock Biotech an outperform vote.
Burning Rock Biotech has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Sera Prognostics has lower revenue, but higher earnings than Burning Rock Biotech. Sera Prognostics is trading at a lower price-to-earnings ratio than Burning Rock Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Sera Prognostics beats Burning Rock Biotech on 13 of the 17 factors compared between the two stocks.
Get Burning Rock Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Burning Rock Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:BNR) was last updated on 1/21/2025 by MarketBeat.com Staff
Free BNR Stock Alerts